Shenzhen Salubris Pharmaceuticals is a China-based pharmaceutical company engaged in research, development and commercialization of treatments for serious chronic diseases. Its original drug development emphasizes cardiovascular and related conditions, including programs in blood-pressure control, kidney disease and other areas with unmet medical needs. The company combines marketed medicines with research platforms intended to generate new therapies. Salubris trades on the Shenzhen Stock Exchange under stock code 002294 and is headquartered in Shenzhen.
Futian District, Shenzhen, GuangdongSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters.Sources (1)
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Shenzhen Salubris Pharmaceuticals is a China-based pharmaceutical company engaged in research, development and commercialization of treatments for serious chronic diseases. Its original drug development emphasizes cardiovascular and related conditions, including programs in blood-pressure control, kidney disease and other areas with unmet medical needs. The company combines marketed medicines with research platforms intended to generate new therapies. Salubris trades on the Shenzhen Stock Exchange under stock code 002294 and is headquartered in Shenzhen.
SZSE: 002294
small molecules · biologics · cardiovascular therapeutics
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
SAL0167 is an internally developed cyclic peptide program for hyperlipidemia that received NMPA clinical trial authorization in 2026. Authorization is not treated as evidence of actual dosing.
Business, technology & evidence
2026-07-10Salubris receives trial clearance for cyclic peptide SAL0167 in hyperlipidemia
Shenzhen Salubris Pharmaceuticals is a China-based pharmaceutical company engaged in research, development and commercialization of treatments for serious chronic diseases. Its original drug development emphasizes cardiovascular and related conditions, including programs in blood-pressure control, kidney disease and other areas with unmet medical needs. The company combines marketed medicines with research platforms intended to generate new therapies. Salubris trades on the Shenzhen Stock Exchange under stock code 002294 and is headquartered in Shenzhen.
SecuritiesSZSE: 002294
Program / service
Target / indication
Representative stage
Evidence & scope
SAL0167
Lipid lowering; the specific mechanism requires primary-source confirmation · Hyperlipidemia
IND clearance
Quantitative human results not confirmed in this review
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Salubris announced NMPA clinical-trial clearance for SAL0167 tablets for hyperlipidemia and identified the proprietary candidate as a cyclic peptide. The authorization permits clinical development but does not establish human dosing, quantitative oral exposure, or lipid-lowering efficacy. General statements about cyclic-peptide advantages should not be treated as demonstrated properties of this particular candidate.
